JP2021167338A - 口腔内微生物群の成長促進用組成物及びその使用方法 - Google Patents
口腔内微生物群の成長促進用組成物及びその使用方法 Download PDFInfo
- Publication number
- JP2021167338A JP2021167338A JP2021114152A JP2021114152A JP2021167338A JP 2021167338 A JP2021167338 A JP 2021167338A JP 2021114152 A JP2021114152 A JP 2021114152A JP 2021114152 A JP2021114152 A JP 2021114152A JP 2021167338 A JP2021167338 A JP 2021167338A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oral
- item
- promoting
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 104
- 238000000034 method Methods 0.000 title abstract description 54
- 230000001737 promoting effect Effects 0.000 title abstract description 51
- 241000736262 Microbiota Species 0.000 title abstract 6
- 210000000214 mouth Anatomy 0.000 abstract description 63
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 18
- 235000001014 amino acid Nutrition 0.000 abstract description 16
- 150000001413 amino acids Chemical class 0.000 abstract description 16
- 210000000987 immune system Anatomy 0.000 abstract description 14
- 208000030961 allergic reaction Diseases 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract description 7
- 229930064664 L-arginine Natural products 0.000 abstract description 7
- 235000014852 L-arginine Nutrition 0.000 abstract description 7
- 238000000855 fermentation Methods 0.000 abstract description 6
- 230000004151 fermentation Effects 0.000 abstract description 6
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 2
- 208000023504 respiratory system disease Diseases 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 description 45
- 230000000813 microbial effect Effects 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 26
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 235000000346 sugar Nutrition 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 15
- 150000004676 glycans Chemical class 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 229920001282 polysaccharide Polymers 0.000 description 13
- 239000005017 polysaccharide Substances 0.000 description 13
- 235000014655 lactic acid Nutrition 0.000 description 12
- 239000004310 lactic acid Substances 0.000 description 12
- 150000002016 disaccharides Chemical class 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 6
- 206010039085 Rhinitis allergic Diseases 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 6
- 201000010105 allergic rhinitis Diseases 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 150000002772 monosaccharides Chemical class 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000894007 species Species 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 208000028004 allergic respiratory disease Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 5
- 229940029339 inulin Drugs 0.000 description 5
- 150000003014 phosphoric acid esters Chemical class 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 3
- 229920000945 Amylopectin Polymers 0.000 description 3
- 241001148134 Veillonella Species 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 244000144725 Amygdalus communis Species 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001533204 Veillonella dispar Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001312 aldohexoses Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000021544 chips of chocolate Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- -1 mannose Chemical class 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019220 whole milk chocolate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/719—Pullulans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】被験者に必要な微生物群の成長を促進することでアレルギー性の呼吸器系疾患を治療する製品であって、L−アルギニンを含有するアミノ酸成分を含む食用可能な組成物を含み、当該製品に含まれた前記組成物は約10秒〜1時間の時間で少なくとも一部が口腔内に溶解し、必要な微生物群は、乳酸発酵能力を有する1種以上の生菌を含む。
【選択図】なし
Description
従って、口腔内微生物群の成長促進物質を含む組成物及びその使用方法を提供する必要があり、当該組成物は口腔内微生物群によって健康を促進する作用を有し、口腔内微生物群を改善することで免疫系の健康を改善するため、アレルギー反応を改善する効果を有する。
L−アルギニンを含有するアミノ酸成分を含む食用可能な組成物を提供することを含み、
提供された組成物は被験者の口腔内に含まれ、且つ、少なくとも一部が被験者の口腔内に溶解し、前記組成物の口腔内に保持される時間は毎日少なくとも約10秒〜1時間で、少なくとも2日継続する。
特定の実施形態では例えば以下の項目(1)が提供される:
(項目1)
被験者の口腔内で必要な微生物群の成長を促進することでアレルギー性の呼吸器系疾患を治療する方法であって、
L−アルギニンを含有するアミノ酸成分を含む食用可能な組成物を提供し、
提供された組成物は被験者の口腔内に含まれ、且つ、少なくとも一部が被験者の口腔内に溶解し、前記組成物の口腔内に保持される時間は毎日少なくとも約10秒〜1時間で、少なくとも2日以上継続することを特徴とする方法。
(項目2)
前記組成物は担体の形式で提供されることを特徴とする項目1に記載の方法。
(項目3)
前記担体は固体、粉末又は液体であることを特徴とする項目4に記載の方法。
(項目4)
前記担体は咀嚼錠、食用可能なカプセル、ペースト剤及び食品の1種以上であることを特徴とする項目4に記載の方法。
(項目5)
前記組成物は口腔内で2日〜約60日連続して保持されることを特徴とする項目1に記載の方法。
(項目6)
口腔に前記組成物を付与する前に、口腔の内表面から一部のバイオフィルムを除去することを特徴とする項目1に記載の方法。
(項目7)
一部の前記バイオフィルムの除去方法として、32℃〜54℃の温度に加熱された液体を使用して口腔を洗い流す且つ/又は口腔を擦ることを含むことを特徴とする項目1に記載の方法。
(項目8)
前記アミノ酸はL−システイン、DL−アスパラギン酸、L−グルタミン酸、L−セリン及びL−チロシンの少なくとも1種をさらに含むことを特徴とする項目1に記載の方法。
(項目9)
前記アミノ酸含有成分の重量パーセントは約0.1〜99.9wt%であることを特徴とする項目1に記載の方法。
(項目10)
前記組成物の成分はさらに糖を含み、前記糖は、単糖、二糖、オリゴ糖及び多糖の1種以上を含むことを特徴とする項目1に記載の方法。
(項目11)
前記糖は、マンノース、ラクトース、マルトース、セロビオース、トレハロース及びラフィノースの1種以上を含むことを特徴とする項目10に記載の方法。
(項目12)
前記組成物は多糖の重合体をさらに含むことを特徴とする項目10に記載の方法。
(項目13)
前記多糖の重合体はアミロペクチン及びイヌリンの1種以上を含むことを特徴とする項目12に記載の方法。
(項目14)
前記糖の前記組成物における重量パーセントは約0.1〜99.9wt%であることを特徴とする項目10に記載の方法。
(項目15)
前記糖の前記組成物における重量パーセントは約0.5〜95wt%であることを特徴とする項目10に記載の方法。
(項目16)
前記組成物及び口腔の少なくとも一方は生菌を含み、前記生菌は乳酸を生成する細菌及び乳酸発酵能力を有する細菌を含むことを特徴とする項目1に記載の方法。
(項目17)
被験者に必要な微生物群の成長を促進することでアレルギー性の呼吸器系疾患を治療する製品であって、L−アルギニンを含有するアミノ酸成分を含む食用可能な組成物を含み、
当該製品に含まれた前記組成物は約10秒〜1時間の時間で少なくとも一部が口腔内に溶解することを特徴とする製品。
(項目18)
前記組成物の成分はさらに糖を含み、前記糖は単糖、二糖、オリゴ糖及び多糖の1種以上を含むことを特徴とする項目17に記載の製品。
(項目19)
前記糖はマンノース、ラクトース、マルトース、セロビオース、トレハロース及びラフィノースの1種以上を含むことを特徴とする項目18に記載の製品。
(項目20)
前記組成物及び口腔内の少なくとも一方はさらに生菌を含み、前記生菌は乳酸を生成する細菌及び乳酸発酵能力を有する細菌を含むことを特徴とする項目18に記載の製品。
特定の実施形態では例えば以下の項目(2)が提供される:
(項目1)
治療を必要とする被験者の口腔内で必要な微生物群の成長を促進することでアレルギー性の呼吸器系疾患を治療する方法であって、
L−アルギニンを含有するアミノ酸成分を含む事前に製造されたプロバイオティクスの食用可能な組成物を提供し、
提供された組成物は被験者の口腔内に含まれ、且つ、少なくとも一部が被験者の口腔内に溶解し、前記組成物の口腔内に保持される時間は毎日少なくとも約10秒〜1時間で、少なくとも2日以上継続することを特徴とする方法。
(項目2)
前記組成物は担体の形式で提供されることを特徴とする項目1に記載の方法。
(項目3)
前記担体は固体、粉末又は液体であることを特徴とする項目2に記載の方法。
(項目4)
前記担体は咀嚼錠、食用可能なカプセル、ペースト剤及び食品の1種以上であることを特徴とする項目2に記載の方法。
(項目5)
前記組成物は口腔内で2日〜約60日連続して保持されることを特徴とする項目1に記載の方法。
(項目6)
口腔に前記組成物を付与する前に、口腔の内表面から一部のバイオフィルムを除去することを特徴とする項目1に記載の方法。
(項目7)
一部の前記バイオフィルムの除去方法として、32℃〜54℃の温度に加熱された液体を使用して口腔を洗い流す且つ/又は口腔を擦ることを含むことを特徴とする項目1に記載の方法。
(項目8)
前記アミノ酸はL−システイン、DL−アスパラギン酸、L−グルタミン酸、L−セリン及びL−チロシンの少なくとも1種をさらに含むことを特徴とする項目1に記載の方法。
(項目9)
前記アミノ酸含有成分の重量パーセントは約0.1〜99.9wt%であることを特徴とする項目1に記載の方法。
(項目10)
前記組成物の成分はさらに糖を含み、前記糖は、単糖、二糖、オリゴ糖及び多糖の1種以上を含むことを特徴とする項目1に記載の方法。
(項目11)
前記糖は、マンノース、ラクトース、マルトース、セロビオース、トレハロース及びラフィノースの1種以上を含むことを特徴とする項目10に記載の方法。
(項目12)
前記組成物は多糖の重合体をさらに含むことを特徴とする項目10に記載の方法。
(項目13)
前記多糖の重合体はアミロペクチン及びイヌリンの1種以上を含むことを特徴とする項目12に記載の方法。
(項目14)
前記糖の前記組成物における重量パーセントは約0.1〜99.9wt%であることを特徴とする項目10に記載の方法。
(項目15)
前記糖の前記組成物における重量パーセントは約0.5〜95wt%であることを特徴とする項目10に記載の方法。
(項目16)
前記組成物及び口腔の少なくとも一方は生菌を含み、前記生菌は乳酸を生成する細菌及び乳酸発酵能力を有する細菌を含むことを特徴とする項目1に記載の方法。
(項目17)
治療を必要とする被験者に必要な微生物群の成長を促進することでアレルギー性の呼吸器系疾患を治療する製品であって、L−アルギニンを含有するアミノ酸成分を含む事前に製造されたプロバイオティクスの食用可能な組成物を含み、
当該製品に含まれた前記組成物は約10秒〜1時間の時間で少なくとも一部が口腔内に溶解することを特徴とする製品。
(項目18)
前記組成物の成分はさらに糖を含み、前記糖は単糖、二糖、オリゴ糖及び多糖の1種以上を含むことを特徴とする項目17に記載の製品。
(項目19)
前記糖はマンノース、ラクトース、マルトース、セロビオース、トレハロース及びラフィノースの1種以上を含むことを特徴とする項目18に記載の製品。
(項目20)
前記組成物及び口腔内の少なくとも一方はさらに生菌を含み、前記生菌は乳酸を生成する細菌及び乳酸発酵能力を有する細菌を含むことを特徴とする項目18に記載の製品。
配合:ラフィノース1杯、トレハロース1杯、マンノース2匙、ラクトース1杯、マルトース1/2杯、アルギニン1/2杯、プルラン2匙、イヌリン1杯、精製赤糖1杯、コーンシロップ1/2杯、蜂蜜1/2杯、ミルクチョコレート1杯、チョコチップ1杯、焼きアーモンド(小片)1/4杯、シナモン1/4匙、バニラエキス1/4匙。
Claims (1)
- 明細書に記載の発明。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/495,188 US9795579B1 (en) | 2017-04-24 | 2017-04-24 | Oral microbiota promoting method |
US15/495,188 | 2017-04-24 | ||
JP2020507984A JP7290869B2 (ja) | 2017-04-24 | 2018-04-13 | 口腔内微生物群の成長促進用組成物及びその使用方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020507984A Division JP7290869B2 (ja) | 2017-04-24 | 2018-04-13 | 口腔内微生物群の成長促進用組成物及びその使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021167338A true JP2021167338A (ja) | 2021-10-21 |
Family
ID=60082814
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020507984A Active JP7290869B2 (ja) | 2017-04-24 | 2018-04-13 | 口腔内微生物群の成長促進用組成物及びその使用方法 |
JP2021114152A Pending JP2021167338A (ja) | 2017-04-24 | 2021-07-09 | 口腔内微生物群の成長促進用組成物及びその使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020507984A Active JP7290869B2 (ja) | 2017-04-24 | 2018-04-13 | 口腔内微生物群の成長促進用組成物及びその使用方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9795579B1 (ja) |
EP (1) | EP3609488A4 (ja) |
JP (2) | JP7290869B2 (ja) |
KR (2) | KR20190141707A (ja) |
CN (1) | CN110520119A (ja) |
AU (1) | AU2018257624B2 (ja) |
WO (2) | WO2018200223A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9795579B1 (en) * | 2017-04-24 | 2017-10-24 | Knoze Jr. Corporation | Oral microbiota promoting method |
US10842811B2 (en) | 2018-02-28 | 2020-11-24 | The Trustees Of Columbia University In The City Of New York | Inulin for preventing antibiotic resistant infection and pathogen colonization |
EP4017462A1 (en) | 2019-12-16 | 2022-06-29 | Colgate-Palmolive Company | Oral care compositions containing inulin |
EP4084784A4 (en) * | 2020-01-13 | 2024-01-17 | Univ Monash | COMPOSITIONS AND METHODS |
JPWO2022145325A1 (ja) * | 2020-12-28 | 2022-07-07 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006049286A1 (ja) * | 2004-11-02 | 2006-05-11 | Ajinomoto Co., Inc. | アレルギー性疾患予防・治療剤 |
WO2014200334A1 (en) * | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
US7790678B1 (en) * | 1999-08-17 | 2010-09-07 | Immunopath Profile, Inc. | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
CN1396908A (zh) * | 2000-01-28 | 2003-02-12 | 宝洁公司 | 美味的精氨酸化合物及其用于心血管健康的应用 |
US20040258630A1 (en) * | 2003-06-23 | 2004-12-23 | Boyd Thomas J. | Antiplaque breath freshening consumable film |
RU2426438C2 (ru) * | 2006-12-06 | 2011-08-20 | ЗАО "Академия-Т" | Синбиотическая композиция для коррекции нарушений микробиоценоза кишечника и повышения общей резистентности организма и способ ее получения (варианты) |
ES2665002T3 (es) * | 2007-03-05 | 2018-04-24 | Om Pharma | Extracto bacteriano para trastornos respiratorios y procedimiento para su preparación |
JP5554994B2 (ja) * | 2007-11-19 | 2014-07-23 | 株式会社カネカ | 乳酸菌含有製剤 |
RU2375923C2 (ru) * | 2008-01-18 | 2009-12-20 | ЗАО "Академия-Т" | Специализированный белковый продукт для питания спортсменов |
US20100055082A1 (en) * | 2008-09-04 | 2010-03-04 | Jacques Alain Bauer | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
WO2012130627A1 (en) * | 2011-03-31 | 2012-10-04 | Nestec S.A. | Nutritional compositions for increasing arginine levels and methods of using same |
BR112013026082A2 (pt) * | 2011-04-12 | 2019-09-24 | Nestec Sa | composições nutricionais incluindo ácidos graxos de cadeia ramificada para melhorar função de barreira intestinal |
WO2014151329A1 (en) * | 2013-03-15 | 2014-09-25 | Aerodesigns, Inc. | Particles for aerosolizing apparatus |
AU2014326756B2 (en) * | 2013-09-24 | 2019-08-29 | The Regents Of The University Of Michigan | Compositions and method for destabilizing, altering, and dispersing biofilms |
CN103520719B (zh) * | 2013-10-24 | 2016-11-23 | 邹潮 | 一种抗体口含制品及其制备方法 |
AU2013408772B2 (en) * | 2013-12-27 | 2017-04-20 | Colgate-Palmolive Company | Prebiotic oral care compositions containing amino acids |
CN104435000A (zh) * | 2014-11-12 | 2015-03-25 | 江南大学 | 乳酸菌对支气管哮喘治疗中的应用 |
KR101734653B1 (ko) * | 2015-06-23 | 2017-05-11 | 서울대학교산학협력단 | 아미노글리코시드계 항생제 및 프로바이오틱스를 포함하는 아프타 구내염 예방 또는 치료용 약학적 조성물 |
EP3397076A1 (en) * | 2015-12-29 | 2018-11-07 | N.V. Nutricia | Fermented formula with non-digestible oligosaccharides |
CN105901678A (zh) * | 2016-04-15 | 2016-08-31 | 邵素英 | 一种木耳益生菌功能性食品 |
CN106857856A (zh) * | 2017-01-14 | 2017-06-20 | 威海紫光科技园有限公司 | 一种有益于呼吸系统的复合益生菌产品 |
US9795579B1 (en) * | 2017-04-24 | 2017-10-24 | Knoze Jr. Corporation | Oral microbiota promoting method |
US10398670B2 (en) * | 2017-04-24 | 2019-09-03 | Knoze Jr. Corporation | Oral microbiota promotion for oral and/or sinus infections |
-
2017
- 2017-04-24 US US15/495,188 patent/US9795579B1/en active Active
- 2017-09-15 US US15/706,177 patent/US11364217B2/en active Active
-
2018
- 2018-04-13 KR KR1020197033975A patent/KR20190141707A/ko not_active IP Right Cessation
- 2018-04-13 WO PCT/US2018/027604 patent/WO2018200223A1/en unknown
- 2018-04-13 JP JP2020507984A patent/JP7290869B2/ja active Active
- 2018-04-13 AU AU2018257624A patent/AU2018257624B2/en active Active
- 2018-04-13 KR KR1020227007264A patent/KR20220034925A/ko not_active Application Discontinuation
- 2018-04-13 CN CN201880022770.2A patent/CN110520119A/zh active Pending
- 2018-04-13 EP EP18790555.9A patent/EP3609488A4/en active Pending
- 2018-09-13 WO PCT/US2018/050898 patent/WO2019055665A1/en active Application Filing
-
2021
- 2021-07-09 JP JP2021114152A patent/JP2021167338A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006049286A1 (ja) * | 2004-11-02 | 2006-05-11 | Ajinomoto Co., Inc. | アレルギー性疾患予防・治療剤 |
WO2014200334A1 (en) * | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
Non-Patent Citations (1)
Title |
---|
ARCHIVES OF ORAL BIOLOGY, vol. 73, JPN6020037156, January 2017 (2017-01-01), pages 79 - 87, ISSN: 0005004024 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018257624A1 (en) | 2019-12-05 |
US9795579B1 (en) | 2017-10-24 |
EP3609488A4 (en) | 2020-05-13 |
CN110520119A (zh) | 2019-11-29 |
KR20220034925A (ko) | 2022-03-18 |
KR20190141707A (ko) | 2019-12-24 |
EP3609488A1 (en) | 2020-02-19 |
US20180303781A1 (en) | 2018-10-25 |
US11364217B2 (en) | 2022-06-21 |
JP2020517746A (ja) | 2020-06-18 |
AU2018257624B2 (en) | 2021-07-08 |
WO2018200223A1 (en) | 2018-11-01 |
WO2019055665A1 (en) | 2019-03-21 |
JP7290869B2 (ja) | 2023-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11083760B2 (en) | Oral microbiota composition for oral and/or sinus infections | |
JP2021167338A (ja) | 口腔内微生物群の成長促進用組成物及びその使用方法 | |
US11478423B2 (en) | Self-film-forming composition for oral care | |
KR102503163B1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물 | |
CN113832062B (zh) | 一种副干酪乳杆菌lc86及其在预防或治疗龋齿和牙周炎上的应用 | |
Badiyani et al. | Chocolate disinfectant: effectiveness of cocoa bean husk extract on Streptococcus mutans in used toothbrushes | |
JP7171264B2 (ja) | 腸バリア改善用組成物 | |
US10398670B2 (en) | Oral microbiota promotion for oral and/or sinus infections | |
JPS58212780A (ja) | ビフイドバクテリウム菌の増殖促進物質 | |
US10471033B2 (en) | Oral microbiota promotion for immune system associated inflammations | |
US11896630B2 (en) | Composition for a formulated oral prebiotic edible composition | |
US20190343899A1 (en) | Oral Microbiota Transformation for the Relief of Immune System Associated Inflammations | |
JP5560472B2 (ja) | インフルエンザウイルス感染症の治療剤 | |
WO2000030661A1 (fr) | Compositions bacteriostatiques contre les salmonelles | |
US20220304967A1 (en) | Oral microbiota promoting composition cross-reference to related applications | |
KR20120055814A (ko) | 구맥 추출물을 유효성분으로 함유하는 구강세균 억제용 항균 조성물 | |
JP2004203784A (ja) | 8−ハイドロキシ−2′−デオキシグアノシン生成抑制剤とその用途 | |
CZ31784U1 (cs) | Univerzální přípravek pro zvýšení celkové obranyschopnosti organismu, pro prevenci, profylaxi a léčbu akné a dalších kožních onemocnění | |
JP2005089437A (ja) | 点鼻腔洗浄組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230327 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231024 |